What is the recommended dose of Lovenox (enoxaparin) for Deep Vein Thrombosis (DVT) prophylaxis in a patient weighing 114kg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Enoxaparin Dosing for DVT Prophylaxis in a 114kg Patient

For DVT prophylaxis in a 114kg patient, the recommended dose of enoxaparin is 40mg subcutaneously once daily.

Rationale for Dosing Recommendation

The recommended prophylactic dose of enoxaparin for DVT prevention is supported by multiple clinical practice guidelines:

  • The American Society of Clinical Oncology (ASCO) guidelines specify that for hospitalized patients requiring DVT prophylaxis, enoxaparin should be dosed at 40mg once daily 1.
  • The National Comprehensive Cancer Network (NCCN) guidelines similarly recommend enoxaparin 40mg once daily for DVT prophylaxis in hospitalized patients 1.

This standard prophylactic dose of 40mg once daily applies regardless of weight for most patients, including those with obesity. Unlike therapeutic dosing for established DVT/PE treatment (which uses weight-based dosing), prophylactic dosing generally uses fixed doses.

Special Considerations for Obese Patients

For patients with obesity, particularly those with BMI ≥40 kg/m² (class 3 obesity), some additional considerations apply:

  • The European Society of Cardiology consensus statement indicates that for class 1-2 obesity (BMI 30-40), no change in the standard prophylactic dose is needed 1.
  • For class 3 obesity (BMI >40), some experts suggest increasing the daily dose or frequency (twice daily dosing) for high-risk patients 1.

With a weight of 114kg, the patient likely falls into class 2 obesity (depending on height), so the standard 40mg once daily dose would still be appropriate.

Monitoring Considerations

  • Anti-Xa monitoring is not routinely required for prophylactic dosing but may be considered in patients with severe obesity (BMI >40) 1, 2.
  • For patients with renal impairment (CrCl <30 mL/min), a dose reduction to 30mg once daily would be recommended 1.

Duration of Prophylaxis

  • For hospitalized medical patients, prophylaxis should continue for the length of hospital stay or until the patient is fully ambulatory 1.
  • For surgical patients, prophylaxis should continue for at least 7-10 days, with extended prophylaxis for up to 4 weeks considered for high-risk patients 1.

Alternative Prophylactic Options

If enoxaparin is contraindicated or unavailable, alternative options include:

  • Unfractionated heparin 5,000 units subcutaneously every 8 hours 1
  • Dalteparin 5,000 units subcutaneously once daily 1
  • Fondaparinux 2.5mg subcutaneously once daily 1

Important Caveats

  • Ensure there are no contraindications to pharmacologic prophylaxis such as active bleeding, severe thrombocytopenia, or recent neurosurgery.
  • For patients with high bleeding risk, mechanical prophylaxis with intermittent pneumatic compression devices should be considered.
  • The prophylactic dose (40mg daily) should not be confused with the therapeutic dose used for treatment of established DVT/PE (1mg/kg twice daily or 1.5mg/kg once daily).

Remember that this recommendation is specifically for DVT prophylaxis. If the patient has an established DVT requiring treatment rather than prophylaxis, a different weight-based dosing regimen would be appropriate.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of Deep Vein Thrombosis with Enoxaparin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.